Literature DB >> 18664550

Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.

Yvonne Will1, James A Dykens, Sashi Nadanaciva, Brad Hirakawa, Joseph Jamieson, Lisa D Marroquin, James Hynes, Shem Patyna, Bart A Jessen.   

Abstract

Cardiovascular disease has recently been suggested to be a significant complication of cancer treatment with several kinase inhibitors. In some cases, the mechanisms leading to cardiotoxicity are postulated to include mitochondrial dysfunction, either as a primary or secondary effect. Detecting direct effects on mitochondrial function, such as uncoupling of oxidative phosphorylation or inhibition of electron transport chain components, as well as identifying targets within the mitochondrial electron transport chain, can be accomplished in vitro. Here, we examined the effects of the tyrosine kinase inhibitor drugs imatinib, dasatinib, sunitinib, and sorafenib on ATP content in H9c2 cells grown under conditions where cells are either glycolytically or aerobically poised. Furthermore, we measured respiratory capacity of isolated rat heart mitochondria in the presence of the four kinase inhibitors and examined their effect on each of the oxidative phosphorylation complexes. Of the four kinase inhibitors examined, only sorafenib directly impaired mitochondrial function at clinically relevant concentrations, potentially contributing to the cytotoxic effect of the drug. For the other three kinase inhibitors lacking direct mitochondrial effects, altered kinase and other signaling pathways, are a more reasonable explanation for potential toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664550     DOI: 10.1093/toxsci/kfn157

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  63 in total

Review 1.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 2.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

3.  Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.

Authors:  Bernhard Gillissen; Anja Richter; Antje Richter; Robert Preissner; Klaus Schulze-Osthoff; Frank Essmann; Peter T Daniel
Journal:  J Biol Chem       Date:  2017-02-01       Impact factor: 5.157

Review 4.  High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.

Authors:  Genevieve Conant; Benjamin Fook Lun Lai; Rick Xing Ze Lu; Anastasia Korolj; Erika Yan Wang; Milica Radisic
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

Review 5.  Assessing mitochondrial dysfunction in cells.

Authors:  Martin D Brand; David G Nicholls
Journal:  Biochem J       Date:  2011-04-15       Impact factor: 3.857

6.  Mitochondrial dysfunction induced by leflunomide and its active metabolite.

Authors:  Jiekun Xuan; Zhen Ren; Tao Qing; Letha Couch; Leming Shi; William H Tolleson; Lei Guo
Journal:  Toxicology       Date:  2018-02-08       Impact factor: 4.221

Review 7.  Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity.

Authors:  Cheavar A Blair; Beth L Pruitt
Journal:  Adv Healthc Mater       Date:  2020-04-09       Impact factor: 9.933

Review 8.  Heart failure associated with sunitinib: lessons learned from animal models.

Authors:  Colin F Greineder; Sarah Kohnstamm; Bonnie Ky
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

Review 9.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

10.  Imatinib activates pathological hypertrophy by altering myocyte calcium regulation.

Authors:  Larry A Barr; Catherine A Makarewich; Remus M Berretta; Hui Gao; Constantine D Troupes; Felix Woitek; Fabio Recchia; Hajime Kubo; Thomas Force; Steven R Houser
Journal:  Clin Transl Sci       Date:  2014-06-16       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.